Bladder Cancer in Women: Improving Diagnosis and Treatment - Jean Hoffman-Censits

Jean Hoffman-Censits joins Alicia Morgans and shares details on the Johns Hopkins women’s bladder cancer program.  This program is created in recognition of the pathway that women frequently take in the diagnosis of their bladder cancer. We often see a delay in the diagnostic process of bladder cancer in women compared to men.  This delay in diagnosis leads to what is thought to be stage migration.  The discussion is centered on educating clinicians and patients about the need to consider the possibility of bladder cancer in women who present with hematuria and to refer these women to a urologist for a timely diagnosis and treatment.   


Jean Hoffman-Censits, MD. is a genitourinary medical oncologist at the Greenberg Bladder Cancer Institute and the Co-Director, Women’s Bladder Cancer Program at Sidney Kimmel Cancer Center at Johns Hopkins. Her clinical and research interest is in the treatment and development of novel therapies for cancers of the bladder, ureter and renal pelvis. She attended Jefferson Medical College, Medical School and spent her residency and fellowship at Thomas Jefferson University Hospital and the Fox Chase Cancer Center in Philadelphia, PA, respectively. Dr. Hoffman-Censits is board-certified to practice Internal Medicine and Medical Oncology and administers chemotherapy and cytoscopy to a patients with a range of urogential cancers. Her extensive publications cover a range of genitourinary cancer topics, including “Identification of Distinct Basal and Luminal Subtypes of Muscle-Invasive Bladder Cancer with Different Sensitivities to Frontline Chemotherapy“.

Alicia Morgans, MD, MPH Associate Professor of Medicine in the Division of Hematology/Oncology at the Northwestern University Feinberg School of Medicine in Chicago, Illinois.